Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 7;12(11):1323.
doi: 10.3390/pathogens12111323.

PYED-1 Overcomes Colistin Resistance in Acinetobacter baumannii

Affiliations

PYED-1 Overcomes Colistin Resistance in Acinetobacter baumannii

Maria Stabile et al. Pathogens. .

Abstract

Antibiotic resistance has become more and more widespread over the recent decades, becoming a major global health problem and causing colistin to be increasingly used as an antibiotic of last resort. Acinetobacter baumannii, an opportunistic pathogen that has rapidly evolved into a superbug exhibiting multidrug-resistant phenotypes, is responsible for a large number of hospital infection outbreaks. With the intensive use of colistin, A. baumannii resistance to colistin has been found to increase significantly. In previous work, we identified a deflazacort derivative, PYED-1 (pregnadiene-11-hydroxy-16,17-epoxy-3,20-dione-1), which exhibits either direct-acting or synergistic activity against Gram-positive and Gram-negative species and Candida spp., including A. baumannii. The aim of this study was to evaluate the antibacterial activity of PYED-1 in combination with colistin against both A. baumannii planktonic and sessile cells. Furthermore, the cytotoxicity of PYED-1 with and without colistin was assessed. Our results show that PYED-1 and colistin can act synergistically to produce a strong antimicrobial effect against multidrug-resistant populations of A. baumannii. Interestingly, our data reveal that PYED-1 is able to restore the efficacy of colistin against all colistin-resistant A. baumannii isolates. This drug combination could achieve a much stronger antimicrobial effect than colistin while using a much smaller dosage of the drugs, additionally eliminating the toxicity and resistance issues associated with the use of colistin.

Keywords: antibiofilm molecules; antibiotic adjuvants; corticosteroids; killing kinetics; multidrug-resistant A. baumannii; synergistic activity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Chemical structure of PYED-1.
Scheme 1
Scheme 1
Synthesis of PYED-1.
Figure 2
Figure 2
Time–kill curves of A. baumannii 249 treated with 1 μg/mL colistin (green lines), 16 μg/mL PYED-1 (red lines) or a combination of colistin and PYED-1 at previous concentrations (blue lines). The untreated controls are shown with black lines. Data are mean values from three independent experiments, and error bars represent standard deviations.
Figure 3
Figure 3
Biofilm-formation-inhibition effects of colistin/PYED-1 combination on A. baumannii 249 strain. Data are expressed as the mean ± standard deviation (SD) of three replicates. *** p < 0.001, significance was analyzed by one-way ANOVA.
Figure 4
Figure 4
Effects of PYED-1 and colistin association on erythrocytes. The positive and negative controls were 1% (v/v) Triton X-100 and 1% DMSO solution, respectively. Data are expressed as the mean ± standard deviation (SD) of three replicates. *** p < 0.001, significance was analyzed by one-way ANOVA; ns, not statistically significant.

Similar articles

Cited by

References

    1. Antunes L.C., Visca P., Towner K.J. Acinetobacter baumannii: Evolution of a global pathogen. Pathog. Dis. 2014;71:292–301. doi: 10.1111/2049-632X.12125. - DOI - PubMed
    1. WHO Publishes List of Bacteria for Which New Antibiotics are Urgently Needed. [(accessed on 29 September 2023)]. Available online: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-....
    1. Willyard C. The drug-resistant bacteria that pose the greatest health threats. Nature. 2017;543:15. doi: 10.1038/nature.2017.21550. - DOI - PubMed
    1. Fahy S., O’Connor J.A., Lucey B., Sleator R.D. Hospital Reservoirs of Multidrug Resistant Acinetobacter Species—The Elephant in the Room! Br. J. Biomed. Sci. 2023;80:11098. doi: 10.3389/bjbs.2023.11098. - DOI - PMC - PubMed
    1. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: Emergence of a successful pathogen. Clin. Microbiol. Rev. 2008;21:538–582. doi: 10.1128/CMR.00058-07. - DOI - PMC - PubMed

LinkOut - more resources